Amgen’s Strategic Crossroads: Innovation Meets Intensifying Competition

The biotechnology giant Amgen finds itself navigating a complex landscape where groundbreaking innovation collides with mounting competitive pressures. While the company faces imminent challenges from newly approved biosimilar drugs targeting its key products, it simultaneously advances a promising pipeline of novel therapies that could redefine its future growth trajectory.

Significant headwinds have emerged for Amgen following the U.S. Food and Drug Administration’s approval of BILDYOS® and BILPREVDA®, Read more...

@ boerse-global.de

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt anmelden.